(MedPage Today) — LAS VEGAS — Upadacitinib (Rinvoq) demonstrated durable clinical, endoscopic, and histologic benefit in a large real-world cohort of patients with ulcerative colitis (UC), with many maintaining remission over time and others…
Source link : https://www.medpagetoday.com/meetingcoverage/ccc/119587
Author :
Publish date : 2026-01-26 18:03:00
Copyright for syndicated content belongs to the linked Source.
